Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-136235

Published: 2020

Journal Articles

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134947

Published: 2020

Journal Articles

Bcor Mutations Cooperate with Tet2 Deficiency to Promote RAS Transformation of Mouse Hematopoietic Progenitors

Iman Fares, PhD, Rahul S. Vedula, MD, Shabbir M. Vahanvaty, Christopher S Waters, Marlise R. Luskin, MD, Priti Kumari, M.S., Marie McConkey, PhD, Anne Charles, BS, Kevin Copson, MA, Gregory A. Abel, MDMPH, Richard M. Stone, MD, Benjamin L. Ebert, MDPhD, R. Coleman Lindsley, MD PhD

Blood (2018) 132 (Supplement 1): 888.

https://doi.org/10.1182/blood-2018-99-120096

Published: 2018

Journal Articles

Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study

Anita J Kumar, MD MS, Tobi Henzer, BS, Angie Mae Rodday, PhD MS, Marlise R. Luskin, MD, Wendy Stock, MD, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2018-99-114773

Published: 2018

Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Jonathan Webster, MD, Marlise R. Luskin, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, Daniel J. DeAngelo, MD, Mark J. Levis, MD, Amanda Blackford, Elad Sharon, MD MPH, Howard Streicher, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2018) 132 (Supplement 1): 557.

https://doi.org/10.1182/blood-2018-99-111845

Published: 2018

Journal Articles

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 766.

https://doi.org/10.1182/blood-2018-99-115145

Published: 2018

Journal Articles

Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities

Rahul S. Vedula, MD, Marlise R. Luskin, MD, Kevin Copson, MA, Priti Kumari, M.S., Anne Charles, BS, Annette S. Kim, MD PhD, Elizabeth A Morgan, MD, Gregory A. Abel, MD MPH, Richard M. Stone, MD, Andrew A. Lane, MD PhD, R. Coleman Lindsley, MD, PhD

Blood (2018) 132 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2018-99-118746

Published: 2018

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)

Blood (2017) 130 (Supplement 1): 3906.

https://doi.org/10.1182/blood.V130.Suppl_1.3906.3906

Published: 2017

Journal Articles

Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies

Marlise R. Luskin, MD, Angel M. Cronin, MS, Kevin Copson, MA, Wooram Jung, Martha Wadleigh, MD, Daniel J. DeAngelo, MD, David P. Steensma, MD, Jane Driver, MD MPH, Andrew A. Lane, MD PhD, R. Coleman Lindsley, MD PhD, Gregory A. Abel, MD

Blood (2017) 130 (Supplement 1): 4276.

https://doi.org/10.1182/blood.V130.Suppl_1.4276.4276

Published: 2017

Journal Articles

Patient-Reported Outcomes Associated with Different Treatments for Myelodysplastic Syndromes

Marlise R. Luskin, MD MSCE, Angel M. Cronin, MS, Martha Wadleigh, MD, David P. Steensma, MD, Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Gregory A. Abel, MD MPH

Blood (2016) 128 (22): 3602.

https://doi.org/10.1182/blood.V128.22.3602.3602

Published: 2016

Journal Articles

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis Gimotty, PhD, Catherine Smith, Alison Loren, MD MS, Maria Figueroa, MD, Jenna Harrison, Zhuoxin Sun, PhD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Mark R Litzow, MD, Ross L. Levine, MD, Hugo F. Fernandez, MD, Selina Luger, MD, Martin Carroll, MD, Stephen Master, MD PhD, Gerald Wertheim, MD PhD

Blood (2015) 126 (23): 2591.

https://doi.org/10.1182/blood.V126.23.2591.2591

Published: 2015

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

Jonathan Canaani, MD, Marlise R. Luskin, MD, Alison Loren, MD MS, Colleen Timlin, PharmD, BCOP, James Mangan, MD PhD, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, David L Porter, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2015) 126 (23): 2543.

https://doi.org/10.1182/blood.V126.23.2543.2543

Published: 2015

Journal Articles

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Noelle V. Frey, MDMS, Selina Luger, MD, James Mangan, MD PhD, Alexis Zebrowski, BA, Alison W. Loren, MDMS, Hans Minderman, John Baird, MD, David L Porter, MD, Elizabeth O. Hexner, MD, Anita J. Kumar, MDMS, Marlise R. Luskin, MD, Alexander E Perl, MD, Martin Carroll, MD

Blood (2014) 124 (21): 3758.

https://doi.org/10.1182/blood.V124.21.3758.3758

Published: 2014

Journal Articles

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 373.

https://doi.org/10.1182/blood.V124.21.373.373

Published: 2014

Journal Articles

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F. Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2599.

https://doi.org/10.1182/blood.V124.21.2599.2599

Published: 2014

Journal Articles

Next Generation Sequencing (NGS) Identifies an Association Between NPM1 Mutation and Leukemia Cutis

Marlise R. Luskin, MD, Campbell L. Stewart, MD, Jennifer JD Morrissette, PhD, David Lieberman, MS, CGC, David J. Margolis, MD, Alexander E. Perl, MD, Misha A. Rosenbach, MD

Blood (2014) 124 (21): 2341.

https://doi.org/10.1182/blood.V124.21.2341.2341

Published: 2014

Journal Articles

A Measure of DNA Methylation for Predicting Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis A. Gimotty, PhD, Gerald Wertheim, MDPhD, Catherine Smith, Alison R. Sehgal, MD, Selina M. Luger, MD, Stephen R. Master, MDPhD, Alison W. Loren, MD, Martin P. Carroll, MD

Blood (2014) 124 (21): 2345.

https://doi.org/10.1182/blood.V124.21.2345.2345

Published: 2014

Journal Articles

CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation

Ran Reshef, MD, Austin P. Huffman, BA, Amy Gao, BA, Mary Sell, BS MT(ASCP), Marlise R. Luskin, MD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Sunita Dwivedy Nasta, MD, Noelle V. Frey, MDMS, Saar I. Gill, MD PhD, James Mangan, MD PhD, Lee P. Richman, BA, Taku Kambayashi, MDPhD, Edward A. Stadtmauer, MD, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 1260.

https://doi.org/10.1182/blood.V124.21.1260.1260

Published: 2014

Journal Articles

Impact Of Autologous Stem Cell Transplantation In Older Patients With Mantle Cell Lymphoma

Zachary Frosch, BA, Marlise R. Luskin, MD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Alison W. Loren, MD, David L. Porter, MD, Edward A. Stadtmauer, MD, Sunita Dwivedy Nasta, MD

Blood (2013) 122 (21): 3384.

https://doi.org/10.1182/blood.V122.21.3384.3384

Published: 2013

Journal Articles

RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,

Marlise R Luskin, MD, Federico Campigotto, MS, Paul G. Richardson, MD, John Koreth, MBBS, DPhil, Irene M. Ghobrial, MD, Robert Schlossman, MD, Robert J Soiffer, MD, Nikhil C. Munshi, MD, Diane Warren, Muriel Gannon, RN, Kathleen Finn, RN, Kenneth C Anderson, MD, Edie Weller, PhD, Jacob P. Laubach, MD

Blood (2011) 118 (21): 4134.

https://doi.org/10.1182/blood.V118.21.4134.4134

Published: 2011

NARROW

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Bcor Mutations Cooperate with Tet2 Deficiency to Promote RAS Transformation of Mouse Hematopoietic Progenitors

Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia

Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)

Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies

Patient-Reported Outcomes Associated with Different Treatments for Myelodysplastic Syndromes

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Next Generation Sequencing (NGS) Identifies an Association Between NPM1 Mutation and Leukemia Cutis

A Measure of DNA Methylation for Predicting Outcome in De Novo AML

CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation

Impact Of Autologous Stem Cell Transplantation In Older Patients With Mantle Cell Lymphoma

RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only